BridgeBio Pharma (BBIO) Current Assets (2018 - 2026)

BridgeBio Pharma's Current Assets history runs 9 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Current Assets rose 78.56% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 78.56% YoY), while the FY2025 annual figure was $797.7 million, up 10.69% from the prior year.
• Current Assets came in at $1.2 billion for Q1 2026 at BridgeBio Pharma, up from $797.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.2 billion in Q1 2026 to a low of $432.9 million in Q2 2023.
• A 5-year average of $693.0 million and a median of $695.2 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets sank 43.87% in 2023 and soared 88.8% in 2025, its largest moves.
• BridgeBio Pharma's Current Assets stood at $548.9 million in 2022, then retreated by 12.98% to $477.6 million in 2023, then jumped by 50.9% to $720.7 million in 2024, then rose by 10.69% to $797.7 million in 2025, then jumped by 55.6% to $1.2 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $1.2 billion, $797.7 million, and $839.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison